<DOC>
	<DOC>NCT02245256</DOC>
	<brief_summary>To test the effect of low-dose dexmedetomidine for lowering the incidence of postoperative delirium in liver transplant patients in the ICU. Single center prospective randomized placebo controlled clinical trial 0.1mcg/kg/hr of dexmedetomidine or equivalent amount of saline infusion started after induction of anesthesia for liver transplantation and continued until 48 hours after surgery. Outcomes will be assessed up to 1 week or transfer to ward, whichever comes first.</brief_summary>
	<brief_title>Efficacy of Low-dose Dexmedetomidine to Prevent Delirium in Liver Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Delirium</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>Adult patients (18years old or older) undergoing livingdonor or deceaseddonor liver transplantation Pediatric patients (under 18 years) Pregnancy Patients who are unresponsive at baseline, who have neurologic deficits at baseline, or who are allergic to dexmedetomidine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>delirium</keyword>
	<keyword>incidence</keyword>
	<keyword>dexmedetomidine</keyword>
</DOC>